Effect of Vernonia Cinerea Lozenges as a Smoking Cessation Aid in Patients With Non-communicable Diseases

Chulalongkorn University

Status: Completed

Conditions: Smoking Cessation

Treatments: Dietary Supplement: Placebo; Dietary Supplement: Vernonia cinerea

Study type: Interventional

Funder types: Other

Identifiers

NCT06268002

5876557033

Details and patient eligibility

About

Vernonia cinerea is an herbal which has been recorded in many Thai herbal formulation and Thai traditional medicine has used this herbal for treating various diseases included hypertension, asthma, fever, hepatitis, kidney stone and smoking cessation. Now aday there are more interest for using Vernonia cinerea as a medication to aid smoker to quit smoking because it is cheaper than other current therapeutic medications. The objective of this study is to evaluate efficacy and safety of Vernonia cinerea lozenge for smoking cessation when compared to placebo.

Full description

This study is a multicenter randomized, paralleled, double blind, controlled trial. This study will include 260 patients from Lerdsin hospital, Chest institute, Phramongkutklao hospital, Maharaj Nakorn Chiang Mai Hospital and Paolo Memorial Phaholyothin hospital who would like to quit smoke. Patients will be assigned into two groups, Vernonia cinerea group (n=130) and placebo group (n=130), both groups will be instructed to take one lozenge three times a day for three months. The two groups will receive individual counseling about smoking cessation technique by trained healthcare professional on every visit. The main primary outcome for this study is continuous abstinence rate (CAR), define as self-report of no cigarette smoking, not even a puff since target quit date, plus passed biochemical validation for 1 month.

Enrollment: 93 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age at least 18 years old
• Have at least 1 underlying non-communicable disease include hypertension, diabetes, dyslipidemia, cardiovascular diseases, cerebrovascular diseases, stable asthma (defined as no asthmatic exacerbation for the preceding 4 weeks necessitating oral prednisolone or an increased use of inhaled corticosteroid, the use of rescue treatment no more than three times a week, and with no clinical indication for change in treatment medication) COPD stage A-C according to GOLD guideline, chronic kidney diseases
• Smoke 10 cigarettes or over per day at least 1 month prior to study
• Desired to quit smoking
• Consent to participate in study

Exclusion criteria

• Renal dysfunction (GFR < 30 ml/mins/1.73m2)
• Liver dysfunction (Child-Pugh score C)
• Hyperkalemia (serum potassium ≥ 5 mEq/L)
• Documented of active depression or psychosis
• Active cancer
• History of acute coronary syndrome in previous 4 weeks
• Known case of pregnancy or lactation
• Use other tobacco products or other addictive substances except alcohol
• Use other smoking cessation drugs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

93 participants in 2 patient groups, including a placebo group

Vernonia cinerea group

Experimental group

Description:

1 lozenges 3 times per day

Treatment:

Dietary Supplement: Vernonia cinerea

Placebo group

Placebo Comparator group

Description:

1 placebo lozenges 3 times per day

Treatment:

Dietary Supplement: Placebo